Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Theodore F, Logan"'
Autor:
Daniel J. George, Theodore F. Logan, Robert Jones, Andrew B. Nixon, Lisa Pickering, Joel Picus, Ulka N. Vaishampayan, Christian K. Kollmannsberger, Qian Yang, Christopher W. Ryan, Jorge A. Garcia, Andrew Protheroe, Andrea Carmack, Susan Halabi, Andrew J. Armstrong, Walter M. Stadler, Robert E. Hawkins, Igor Puzanov, John D. Hainsworth, Tim Eisen
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(12)
Purpose: Biomarkers are needed in patients with non–clear cell renal cell carcinomas (NC-RCC) to inform treatment selection but also to identify novel therapeutic targets. We thus sought to profile circulating angiokines in the context of a randomi
Autor:
Mario Sznol, F. Stephen Hodi, Paolo A. Ascierto, Jaclyn Neely, David F. McDermott, Ignacio Melero, Michele Maio, Walter J. Urba, Theodore F. Logan, Satyendra Suryawanshi, Neil H. Segal, Caroline Robert, Suba Krishnan, Tara C. Gangadhar, Henrik Schmidt, Vanna Chiarion-Sileni, Maria Jure-Kunkel, Ronald Levy, Omid Hamid, Holbrook E Kohrt
Publikováno v:
Segal, N H, Logan, T F, Hodi, F S, McDermott, D, Melero, I, Hamid, O, Schmidt, H, Robert, C, Chiarion-Sileni, V, Ascierto, P A, Maio, M, Urba, W J, Gangadhar, T C, Suryawanshi, S, Neely, J, Jure-Kunkel, M, Krishnan, S, Kohrt, H, Sznol, M & Levy, R 2017, ' Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody ', Clinical Cancer Research, vol. 23, no. 8, pp. 1929-1936 . https://doi.org/10.1158/1078-0432.CCR-16-1272
Purpose: Urelumab is an agonist antibody to CD137 with potential application as an immuno-oncology therapeutic. Data were analyzed to assess safety, tolerability, and pharmacodynamic activity of urelumab, including the dose selected for ongoing devel
Autor:
Alexandra S. Bailey, Jeffrey A. Sosman, Su Chun Cheng, Bradley C. Leibovich, Michael Ka Keu Wong, Rupal S. Bhatt, Eugene D. Kwon, Leslie Oleksowicz, Joseph I. Clark, Leonard Joseph Appleman, Sabina Signoretti, Robert A. Figlin, Marc S. Ernstoff, David F. McDermott, Ulka N. Vaishampayan, Nikhil I. Khushalani, James W. Mier, Kim Margolin, Brendan D. Curti, Theodore F. Logan, David J. Panka, Allan J. Pantuck, Janice P. Dutcher, Fairooz F. Kabbinavar, Michael B. Atkins, Arie S. Belldegrun, Meredith M. Regan
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 21, iss 3
Purpose: High-dose aldesleukin (HD IL2) received FDA approval for the treatment of metastatic renal cell carcinoma (MRCC) in 1992, producing a 14% objective response rate (ORR) and durable remissions. Retrospective studies suggested that clinical and
Autor:
R. C. Jewell, Kevin M. Koch, Theodore F. Logan, James W. Mier, Jill Weisenbach, Linda M. Thurmond, Suzanne Roberts, William N. Bell, S. Kathman, Mohammed M. Dar, Michael J. Robertson, Lini N. Pandite, L. Kirby, Henry B. Koon, Coreen Oei, Michael B. Atkins
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 12(14 Pt 1)
Purpose: Interleukin-18 (IL-18) is an immunostimulatory cytokine with antitumor activity in preclinical animal models. A phase I study of recombinant human IL-18 (rhIL-18) was done to determine the toxicity, pharmacokinetics, and biological activitie
Autor:
Tomohide, Tatsumi, Lisa S, Kierstead, Elena, Ranieri, Loreto, Gesualdo, Francesco P, Schena, James H, Finke, Ronald M, Bukowski, Vladimir, Brusic, John, Sidney, Alessandro, Sette, Theodore F, Logan, Yvette L, Kasamon, Craig L, Slingluff, John M, Kirkwood, Walter J, Storkus
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 9(3)
CD4+ T cells modulate the magnitude and durability of CTL responses in vivo and may serve as potent effector cells within the tumor microenvironment. The current study was undertaken to define novel epitopes from the broadly expressed tumor antigen M